USB’s expertise in reagents will aid company’s efforts to provide new genetic analysis tests.

Affymetrix plans to pay $75 million for USB. Affymetrix believes that USB’s line of molecular biology and biochemical reagent products will help the company accelerate development of genetic analysis solutions.


USB is a developer, manufacturer, and supplier of enzymes, reagents, and kits for life science research and industrial applications. The company’s offerings are grouped into three major categories consisting of molecular biology enzymes and kits, biochemical reagents, and products used in membrane protein research applications.


The transaction is expected to close in the first quarter of 2008. The acquisition is anticipated to be modestly accretive to 2008 earnings per share, according to Kevin King, president of Affymetrix.

Previous articleGalapagos Banks over $10M as a Milestone Fee from GSK
Next articleLilly Coughs Up $87M Upfront for BioMS Medical’s MS Candidate